Biosimilars
Article
Biosimilars help lower costs and foster innovation in pharmacy benefits
By creating competition that can significantly reduce the prices of biologic medications, biosimilars create financial headroom for plan sponsors to offer coverage for innovative drug treatments.
Read More
Article
Express Scripts continues efforts to lower drug costs and ensure streamlined patient access to innovative biosimilars
Read More
Article
Leveraging biosimilars to drive savings and support patient access
July 01, 2024
By the end of 2024, 3 FDA-approved biosimilars to Stelara for patients living with inflammatory conditions will be closer to launch, enabling lower total drug spend.
Article
Evernorth chief bullish on driving affordability through biosimilars and access through guided care
Read More
Article
Press Release
Evernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June
Read More